Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jan Menne

Showing results (21-30 of 113) with videos related to

Pageof 12
Sort By:
Current Hypertension Reports|April 27, 2016
Finerenone: a New Mineralocorticoid Receptor Antagonist Without Hyperkalemia: an Opportunity in Patients with CKD?Hermann Haller, Anna Bertram, Klaus Stahl, et al.
Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association|April 8, 2009
Inhibition of protein kinase C in diabetic nephropathy--where do we stand?Jan Menne, Matthias Meier, Joon-Keun Park, et al.
Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association|August 29, 2007
Nailing down PKC isoform specificity in diabetic nephropathy two's company, three's a crowdMatthias Meier, Jan Menne, Joon-Keun Park, et al.
Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association|December 11, 2012
Resistant hypertension: baroreflex stimulation as a new toolJan Menne, Jens Jordan, Silvia Linnenweber-Held, et al.
Biomed Research International|October 31, 2017
Molecular Mechanisms and Treatment Strategies in Diabetic Nephropathy: New Avenues for Calcium Dobesilate-Free Radical Scavenger and Growth Factor InhibitionHermann Haller, Linong Ji, Klaus Stahl, et al.
Plos Medicine|December 10, 2019
Acute kidney injury and adverse renal events in patients receiving SGLT2-inhibitors: A systematic review and meta-analysisJan Menne, Eva Dumann, Hermann Haller, et al.
Journal of the Renin-Angiotensin-Aldosterone System : JRAAS|November 4, 2006
Spotlight on renin: intrarenal renin-angiotensin system--important player of the local milieuHermann Haller, Joon-Keun Park, Carsten Lindschau, et al.
Blood Pressure|February 9, 2026
Long-Term Efficacy and Safety of First- and Second-Generation Baroreflex Activation Devices in Refractory Hypertension: A Single Center Retrospective AnalysisJessica Kaufeld, Ruha Younes, Thomas Aper, et al.
Journal of the American Heart Association|April 30, 2014
The Randomized Olmesartan and Diabetes Microalbuminuria Prevention (ROADMAP) observational follow-up study: benefits of RAS blockade with olmesartan treatment are sustained after study discontinuationJan Menne, Eberhard Ritz, Luis M Ruilope, et al.
Journal of the American Society of Nephrology : JASN|June 8, 2007
The continuous erythropoietin receptor activator affects different pathways of diabetic renal injuryJan Menne, Joon-Keun Park, Nelli Shushakova, et al.
Pageof 12

Showing results (21-30 of 113) with videos related to

Sort By:
Pageof 12
Current Hypertension Reports|April 27, 2016
Finerenone: a New Mineralocorticoid Receptor Antagonist Without Hyperkalemia: an Opportunity in Patients with CKD?Hermann Haller, Anna Bertram, Klaus Stahl, et al.
Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association|April 8, 2009
Inhibition of protein kinase C in diabetic nephropathy--where do we stand?Jan Menne, Matthias Meier, Joon-Keun Park, et al.
Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association|August 29, 2007
Nailing down PKC isoform specificity in diabetic nephropathy two's company, three's a crowdMatthias Meier, Jan Menne, Joon-Keun Park, et al.
Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association|December 11, 2012
Resistant hypertension: baroreflex stimulation as a new toolJan Menne, Jens Jordan, Silvia Linnenweber-Held, et al.
Biomed Research International|October 31, 2017
Molecular Mechanisms and Treatment Strategies in Diabetic Nephropathy: New Avenues for Calcium Dobesilate-Free Radical Scavenger and Growth Factor InhibitionHermann Haller, Linong Ji, Klaus Stahl, et al.
Plos Medicine|December 10, 2019
Acute kidney injury and adverse renal events in patients receiving SGLT2-inhibitors: A systematic review and meta-analysisJan Menne, Eva Dumann, Hermann Haller, et al.
Journal of the Renin-Angiotensin-Aldosterone System : JRAAS|November 4, 2006
Spotlight on renin: intrarenal renin-angiotensin system--important player of the local milieuHermann Haller, Joon-Keun Park, Carsten Lindschau, et al.
Blood Pressure|February 9, 2026
Long-Term Efficacy and Safety of First- and Second-Generation Baroreflex Activation Devices in Refractory Hypertension: A Single Center Retrospective AnalysisJessica Kaufeld, Ruha Younes, Thomas Aper, et al.
Journal of the American Heart Association|April 30, 2014
The Randomized Olmesartan and Diabetes Microalbuminuria Prevention (ROADMAP) observational follow-up study: benefits of RAS blockade with olmesartan treatment are sustained after study discontinuationJan Menne, Eberhard Ritz, Luis M Ruilope, et al.
Journal of the American Society of Nephrology : JASN|June 8, 2007
The continuous erythropoietin receptor activator affects different pathways of diabetic renal injuryJan Menne, Joon-Keun Park, Nelli Shushakova, et al.
Pageof 12